I
Isabelle Guillemin
Researcher at Research Triangle Park
Publications - 7
Citations - 260
Isabelle Guillemin is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Dupilumab & Atopic dermatitis. The author has an hindex of 5, co-authored 7 publications receiving 69 citations.
Papers
More filters
Journal ArticleDOI
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study
Jonathan I. Silverberg,Sébastien Barbarot,Abhijit Gadkari,Eric L. Simpson,Stephan Weidinger,Paola Mina-Osorio,Ana B. Rossi,Lysel Brignoli,Grece Saba,Isabelle Guillemin,Miriam C. Fenton,Sebastien Auziere,Laurent Eckert +12 more
TL;DR: In this paper, a cross-sectional, web-based survey of children and adolescents was conducted to estimate the real-world global prevalence of atopic dermatitis in the pediatric population and by disease severity.
Journal ArticleDOI
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Jonathan I. Silverberg,Gil Yosipovitch,Eric L. Simpson,Brian S. Kim,Jashin J. Wu,Laurent Eckert,Isabelle Guillemin,Zhen Chen,Marius Ardeleanu,Ashish Bansal,Mandeep Kaur,Ana B. Rossi,Neil M.H. Graham,Naimish Patel,Abhijit Gadkari +14 more
TL;DR: Across four randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.
Journal ArticleDOI
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Eric L. Simpson,Laurent Eckert,Abhijit Gadkari,Usha G. Mallya,Min Yang,Lauren Nelson,Michelle H. Brown,Matt Reaney,Puneet Mahajan,Isabelle Guillemin,Mark Boguniewicz,David M. Pariser +11 more
TL;DR: The findings confirm that the ADCT is a valid and reliable tool for assessing atopic dermatitis control and provided thresholds to identify meaningful within-person change.
Journal ArticleDOI
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
Michael J. Cork,Michael J. Cork,Diamant Thaçi,Lawrence F. Eichenfield,Peter D. Arkwright,Xian Sun,Zhen Chen,Bolanle Akinlade,Susan Boklage,Isabelle Guillemin,Matthew P. Kosloski,Mohamed A. Kamal,John T. O'Malley,Naimish Patel,N.M.H. Graham,Ashish Bansal +15 more
TL;DR: D dupilumab, a monoclonal antibody inhibiting interleukin (IL)‐4/IL‐13 signalling, significantly improved signs and symptoms with acceptable safety; longer‐term safety and efficacy data are lacking.
Journal ArticleDOI
Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis
Eric L. Simpson,Marjolein S. de Bruin-Weller,Laurent Eckert,Diane Whalley,Isabelle Guillemin,Matthew Reaney,Zhen Chen,Lauren Nelson,Shanshan Qin,Ashish Bansal,Abhijit Gadkari +10 more
TL;DR: In adolescents with moderate-to-severe AD, a within-person change of 6–8 points in POEM and CDLQI scores, independently, can be considered a reasonable responder threshold for clinically meaningful change in each of the two scales.